MAR-GALANTAMINE ER CAPSULE (EXTENDED RELEASE)
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
15-01-2018
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
GALANTAMINE (GALANTAMINE HYDROBROMIDE)
Beschikbaar vanaf:
MARCAN PHARMACEUTICALS INC
ATC-code:
N06DA04
INN (Algemene Internationale Benaming):
GALANTAMINE
Dosering:
24MG
farmaceutische vorm:
CAPSULE (EXTENDED RELEASE)
Samenstelling:
GALANTAMINE (GALANTAMINE HYDROBROMIDE) 24MG
Toedieningsweg:
ORAL
Eenheden in pakket:
30
Prescription-type:
Prescription
Therapeutisch gebied:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0144660005; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2021-05-10
Productkenmerken
1
PRODUCT MONOGRAPH
PR
MAR-GALANTAMINE ER
galantamine hydrobromide extended release capsules
8 mg, 16 mg, 24 mg galantamine base
Cholinesterase Inhibitor
Marcan Pharmaceuticals Inc.
Date of Revision:
77 Auriga Drive, Unit# 4
January 15, 2018
Ottawa, ON, CANADA
K2E 7Z7
Control No.: 212078
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................................
3
CONTRAINDICATIONS
............................................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................................
3
ADVERSE REACTIONS
............................................................................................................................
7
DRUG INTERACTIONS
...........................................................................................................................
12
DOSAGE AND ADMINISTRATION
......................................................................................................
14
OVERDOSAGE
.........................................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
16
STORAGE AND STABILITY
..................................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................................
20
PART II: SCIENTIFIC INFORMATION
..............................................................................................
Lees het volledige document
